Charles Schwab’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.29M | Buy |
635,282
+27,400
| +5% | +$98.6K | ﹤0.01% | 2623 |
|
|
2025
Q1 | $1.82M | Sell |
607,882
-51,645
| -8% | -$154K | ﹤0.01% | 2647 |
|
|
2024
Q4 | $2.21M | Buy |
659,527
+9,370
| +1% | +$31.4K | ﹤0.01% | 2646 |
|
|
2024
Q3 | $2.18M | Buy |
650,157
+50,794
| +8% | +$170K | ﹤0.01% | 2685 |
|
|
2024
Q2 | $1.98M | Sell |
599,363
-12,956
| -2% | -$42.9K | ﹤0.01% | 2701 |
|
|
2024
Q1 | $2.47M | Buy |
612,319
+27,993
| +5% | +$113K | ﹤0.01% | 2534 |
|
|
2023
Q4 | $1.78M | Buy |
584,326
+2,093
| +0.4% | +$6.38K | ﹤0.01% | 2654 |
|
|
2023
Q3 | $1.75M | Buy |
582,233
+8,274
| +1% | +$24.8K | ﹤0.01% | 2639 |
|
|
2023
Q2 | $2.15M | Buy |
573,959
+47,610
| +9% | +$178K | ﹤0.01% | 2525 |
|
|
2023
Q1 | $1.76M | Sell |
526,349
-38,145
| -7% | -$128K | ﹤0.01% | 2557 |
|
|
2022
Q4 | $2.72M | Buy |
564,494
+11,170
| +2% | +$53.7K | ﹤0.01% | 2462 |
|
|
2022
Q3 | $3.15M | Buy |
553,324
+125,603
| +29% | +$715K | ﹤0.01% | 2440 |
|
|
2022
Q2 | $3.04M | Buy |
427,721
+13,124
| +3% | +$93.2K | ﹤0.01% | 2408 |
|
|
2022
Q1 | $2.99M | Buy |
414,597
+19,350
| +5% | +$140K | ﹤0.01% | 2508 |
|
|
2021
Q4 | $3.53M | Buy |
395,247
+2,068
| +0.5% | +$18.5K | ﹤0.01% | 2523 |
|
|
2021
Q3 | $13.8M | Buy |
393,179
+196,840
| +100% | +$6.9M | ﹤0.01% | 1824 |
|
|
2021
Q2 | $4.22M | Buy |
196,339
+107,499
| +121% | +$2.31M | ﹤0.01% | 2429 |
|
|
2021
Q1 | $5.49M | Buy |
88,840
+2,406
| +3% | +$149K | ﹤0.01% | 2252 |
|
|
2020
Q4 | $3.61M | Buy |
+86,434
| New | +$3.61M | ﹤0.01% | 2374 |
|